These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14637073)

  • 21. Adenosine A2A receptor antagonists in Parkinson's disease: still in the running.
    Antonini A; Poewe W
    Lancet Neurol; 2014 Aug; 13(8):748-9. PubMed ID: 25008550
    [No Abstract]   [Full Text] [Related]  

  • 22. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
    Schwarzschild MA; Xu K; Oztas E; Petzer JP; Castagnoli K; Castagnoli N; Chen JF
    Neurology; 2003 Dec; 61(11 Suppl 6):S55-61. PubMed ID: 14663012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?].
    Jost WH; Tönges L
    Fortschr Neurol Psychiatr; 2022 Dec; 90(12):565-570. PubMed ID: 35226930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Istradefylline for Restless Legs Syndrome Associated with Parkinson's Disease.
    Nuermaimaiti M; Oyama G; Kasemsuk C; Hattori N
    Tremor Other Hyperkinet Mov (N Y); 2018; 8():521. PubMed ID: 29423337
    [No Abstract]   [Full Text] [Related]  

  • 26. Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone.
    Khadrawy YA; Salem AM; El-Shamy KA; Ahmed EK; Fadl NN; Hosny EN
    J Diet Suppl; 2017 Sep; 14(5):553-572. PubMed ID: 28301304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenosine A
    Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
    Mov Disord; 2021 Jan; 36(1):268-269. PubMed ID: 33200448
    [No Abstract]   [Full Text] [Related]  

  • 28. Future strategies for the treatment of Parkinson's disease.
    Fahn S
    Adv Neurol; 1993; 60():636-40. PubMed ID: 8420202
    [No Abstract]   [Full Text] [Related]  

  • 29. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
    Cacciari B; Spalluto G; Federico S
    Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiological roles for purines: adenosine, caffeine and urate.
    Morelli M; Carta AR; Kachroo A; Schwarzschild MA
    Prog Brain Res; 2010; 183():183-208. PubMed ID: 20696321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
    Perez-Lloret S; Merello M
    Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.
    Shah U; Hodgson R
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):466-80. PubMed ID: 20597030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.
    Richardson PJ; Kase H; Jenner PG
    Trends Pharmacol Sci; 1997 Sep; 18(9):338-44. PubMed ID: 9345853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A2A receptors in neuroprotection of dopaminergic neurons.
    Pedata F; Pugliese AM; Melani A; Gianfriddo M
    Neurology; 2003 Dec; 61(11 Suppl 6):S49-50. PubMed ID: 14663010
    [No Abstract]   [Full Text] [Related]  

  • 35. [Caffeine in Parkinson's disease].
    Ferré S
    Med Clin (Barc); 2008 Nov; 131(18):710-5. PubMed ID: 19087830
    [No Abstract]   [Full Text] [Related]  

  • 36. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
    Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
    Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure of the adenosine A
    Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caffeine; the Forgotten Potential for Parkinson's Disease.
    Negida A; Elfil M; Attia ; Farahat E; Gabr M; Essam A; Attia D; Ahmed H
    CNS Neurol Disord Drug Targets; 2017; 16(6):652-657. PubMed ID: 27823571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine A2A receptors and neuroprotection.
    Ongini E; Adami M; Ferri C; Bertorelli R
    Ann N Y Acad Sci; 1997 Oct; 825():30-48. PubMed ID: 9369973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
    Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
    Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.